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When it comes to regenerative medicine, mesenchymal stem cells (MSCs) are considered
one of the most promising cell types for use in many cell therapies and bioengineering
protocols. The International Society of Cellular Therapy recommended minimal criteria
for defining multipotential MSC is based on adhesion and multipotency in vitro, and
the presence or absence of select surface markers. Though these criteria help minimize
discrepancies and allow some comparisons of data generated in different laboratories, the
conditions in which cells are isolated and expanded are often not considered. Herein, we
propose and recommend a few procedures to be followed to facilitate the establishment
of quality control standards when working with mesenchymal progenitors isolation and
expansion. Following these procedures, the classic Colony-Forming Unit-Fibroblast (CFU-f)
assay is revisited and three major topics are considered to define conditions and to
assist on protocol optimization and data interpretation. We envision that the creation of a
guideline will help in the identification and isolation of long-term stem cells and short-term
progenitors to better explore their regenerative potential for multiple therapeutic purposes.
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INTRODUCTION
To minimize discrepancies and inconsistencies, and allow com-
parison of data generated in different laboratories, members of
the International Society of Cellular Therapy (ISCT) (Horwitz
et al., 2005) have recommended minimal criteria for defining
multipotential mesenchymal stem cells (MSCs). By ISCT crite-
ria, MSCs must adhere and grow on a substrate in vitro and give
rise to osteoblasts, chondrocytes, adipocytes, and hematopoiesis-
supporting reticular stroma when cultured under proper differ-
entiation conditions. MSCs must also express CD73, CD90, and
CD105, but not express hematopoietic cells and endothelial cells
markers (Barry et al., 1999, 2001; Jones et al., 2002; Horwitz
et al., 2005; Dominici et al., 2006; Sarugaser et al., 2009). Further
investigation unveiled a few other surface markers, among which
CD146 has been demonstrated to be consistently expressed by all
MSCs and progenitors (Bianco et al., 1988; Shih, 1999; Dennis
et al., 2002; Tuli et al., 2003; Zannettino et al., 2003; Sacchetti
et al., 2007).
Growing evidence indicates an intimate relationship between
MSCs and those cells identified as pericytes, since these two
populations demonstrate similar behavior and potential in vitro
and in vivo (Shi and Gronthos, 2003; Sacchetti et al., 2007;
Taichman et al., 2010; Péault, 2012). Pericytes are perivascular
cells which reside on the abluminal side of sinusoids and are
known to express the proteoglycan NG2, alpha smooth mus-
cle actin (αSMA), and Platelet Derived Growth Factor Receptor
(PDGFR) (Andreeva et al., 1998; Crisan et al., 2008a, 2009; Maier
et al., 2010). Similarities to pericytes led to the concept that all
tissues in the body harbor their own population of mesenchymal-
like stem cells. Of note, it is important to stress that these cells are
influenced by the niche they occupy in vivo, making them similar
to each other, but with a few distinct characteristics and differ-
entiation bias. Mesenchymal-like stem cells and progenitors have
been isolated from several tissues, but adipose tissue and bone
marrow are usually indicated as most promising sources of these
cells by those working in the cell therapy and bioengineering fields
(Da Silva Meirelles et al., 2006; Crisan et al., 2008b; Corselli et al.,
2011). Yet to date, no specific or combination of markers can be
used to distinguish multipotential MSCs from committed pro-
genitors. A differentiation cascade, similar to the hematopoietic
system, has not yet been assembled and confirmed.
Friedenstein and coworkers (Friedenstein et al., 1974a,b;
Friedenstein, 1976; Owen and Friedenstein, 1988) were the first to
describe the existence of a second category of progenitors residing
in the marrow cavity, and named them stromal progenitor cells.
His cues came with an in vivo assay, in which bone marrow cells
were loaded into chambers and implanted subcutaneously in rats
(Friedenstein et al., 1966, 1974b). After several weeks of implan-
tation, bone-like mineralized nodules and cuboidal osteoblasts
were observed inside the chambers in the new-formed tissue.
The chamber’s pores were too small and prevented cells from
migrating into or out of the chambers, supporting the concept
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that the new bony tissue formed inside the chambers was exclu-
sively generated from donor cells rather than recipient cells.
Additional studies identified this activity belonging to the non-
hematopoietic stromal fraction. In vitro, they showed that when
bone marrow cells were placed into culture at low density, a
few of them adhered, proliferated, and gave rise to colonies of
fibroblast-like cells (CFU-f). These adherent fibroblast-like cells,
but not the hematopoietic cells, when implanted in vivo, differ-
entiated into bone tissue and bone marrow stroma, confirming
that the bone marrow microenvironment is the niche for two dis-
tinct progenitors populations (Friedenstein et al., 1966, 1974a;
Owen and Friedenstein, 1988). Cells were then named stromal
stem cells. Later, further clonal manipulation and in vivo obser-
vations led different authors to propose different names, such as
mesenchymal stem cells (Caplan, 1991, 2007) and skeletal stem
cells (Bianco, 2011), to define almost the same cell population.
However, it is important to stress that, even though these names
have been used unrestrictedly as synonyms by several different
authors, conceptually and originally, they indicate significant dif-
ferences among the cells, mainly concerning their differentiation
potential.
Although several research groups have described different
strategies to isolate mesenchymal cells, the CFU-f assay has
undergone almost no change since its original description by
Friedenstein and coworkers (Friedenstein et al., 1970, 1974b).
Higher proliferative rates are usually related to the stem cell and
progenitor populations in most normal tissues. It is therefore
assumed that each colony of fibroblast-like cells (CFU-f) orig-
inates from a single stem and/or progenitor cell (Friedenstein
et al., 1966, 1974a,b; Latsinik and Epikhina, 1974; Friedenstein,
1976), and the number of colonies observed represents the num-
ber of mesenchymal progenitors as a fraction of the number of
nucleated cells plated.
For researchers working with mesenchymal cells isolation and
expansion, this is the most widely accepted assay used to quan-
tify progenitors numbers. In the present perspective we addressed
major topics we believe are most relevant regarding a few spe-
cific and distinct aspects of in vitro cell adhesion and growth.
Even though CFU-f assay is very simple to perform, we proposed
three different strategies based on progenitors in vitro clonogenic
potential, which might be helpful to define standard conditions
to optimize in vitro manipulation, and provide data linearity and
reproducibility.
NUMBER OF CELLS IN A COLONY
In the late 1960’s and early 1970’s, Alexander Friedenstein and
colleagues (Friedenstein et al., 1966, 1970) began their journey
into the bone marrow cavity and defined the primary conditions
to quantify a sub-population of, by that time, osteogenic progen-
itors among all bone marrow stromal cells (Friedenstein et al.,
1966, 1982). In the original protocol, single cell suspensions of
bone marrow cells are plated at low-density (104–105 nucleated
cells per cm2) and incubated in DMEM supplemented with fetal
bovine serum (FBS). Seventy-two hours later, the non-adherent
cells are washed out and the adherent fraction is incubated in
fresh culture medium. Culture medium is renewed every 3–4
days over a ten-day culture. After a total of 13 days, the cells
are fixed and further stained in crystal violet, and the colonies
are counted (Satomura et al., 2000; Kuznetsov et al., 2009). It
is assumed in this case that when bone marrow cells are plated
in low-density cultures, the colonies will not reach each other’s
borders supporting that each colony is derived from a single pro-
genitor. However, it is important to keep in mind that colonies
are heterogeneous and, although each one is derived from a
single progenitor, not all display a multilineage differentiation
potential. Many are already committed to a specific lineage, fol-
lowing the hierarchical-like and controlled differentiation cascade
(Muraglia et al., 2000; Sarugaser et al., 2009; Russell et al., 2010).
Colonies also display different sizes and cell distribution within
the cultures, which may correlate to cell differentiation stage
(Figure 1). Additional studies have revealed that ∼30% of all BM
mesenchymal progenitors colonies present trilineage potential—
osteogenic, chondrogenic, and adipogenic—in vitro. Sacchetti
and coworkers (Sacchetti et al., 2007) demonstrated that ∼50%
of the CD146+ clonal mesenchymal progenitors isolated from the
bone marrow cultures give rise to compact bone, but not bone
marrow, when implanted in vivo, indicating that half of the pro-
genitors, upon isolation from an adult bone marrow, are already
committed to the osteogenic lineage.
As for several tissues, cells are classified into three categories:
(1) stem cells, (2) intermediate progenitors and (3) differenti-
ated cells. Typically, differentiated cells possess low proliferation
ability in vitro, while intermediate progenitors present high pro-
liferative rates under stimulus. On the other hand, stem cells are
quiescent cells in vivo, but in vitro, under the proper culture con-
ditions, exit the quiescence stage and become highly proliferative
(Stanley et al., 1971; Urabe et al., 1979; Nicola and Metcalf, 1986;
Oh and Humphries, 2012; Bianco et al., 2013). When analyzed in
this perspective, it is expected that several stromal cell populations
adhere to the culture flask surface in the first three days of cul-
ture, namely differentiated reticular cells, committed progenitors
and stem cells. Only progenitors and stem cells will proliferate to
generate colonies. Regardless progenitors commitment, what fea-
tures each group of cells must present to be identified as a colony?
Based on the original protocol and refinements suggested by sev-
eral laboratories (Wagner et al., 2009; Bianco et al., 2013), only
colonies consisting of more than 50 cells should be classified as
a colony (Kuznetsov et al., 2009). Colonies quantification can be
performed under the microscope, but stained colonies with more
than 50 cells are easily observed directly by the “naked eye.” It
must be acknowledged that growth-promoting activity will vary
from FBS lot to lot, which may change CFU-f results. Thus, a
quality control should be used to screen FBS lots to avoid subop-
timal or “superoptimal” conditions, which may result in changes
in colony formation and impact cell growth and differentiation
(Mannello and Tonti, 2007).
It is clear that cell proliferation status changes accordingly as
FBS is changed, which will considerably impact CFU-f results.
Cell proliferation depends upon growth factors concentration
and, regardless all the controls applied to serum fabrication,
this varies largely from FBS lot to lot. Conversely, it is not
clear how progenitors respond to serum variations. It must
be determined if proliferation of progenitors in vitro follows
a simultaneous or selective growth pattern, the latter being all
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FIGURE 1 | Schematic representation of the suggested correlation between themesenchymal stem cell differentiation cascade and colony size in vitro.
It is frequently inferred that most primitive progenitors give rise to larger colonies compared to those originated from intermediate and committed progenitors.
FIGURE 2 | Two hypotheses discussing the potential differences in the
Colony Forming Efficiency results associated with the usage of
different fetal bovine serum lots. The “Simultaneous Growth
Hypothesis” suggests colonies are similarly affected and respond
simultaneously, proliferating more or less, but in the same proportion. The
“Selective Growth Hypothesis,” suggests that in response to different FBS
lots, a few progenitors will proliferate more than others, as a result of
growth factors concentration and combination.
progenitors will respond differently when FBS lot is changed
(Figure 2). It is expected that all progenitors in a plate respond
similarly (Simultaneous Growth Hypothesis) and, as the FBS lot
is changed, they all may proliferate more or less. It is unclear if this
is what occurs in vitro. Different from the concept that all colonies
will be bigger or smaller, the Selective Growth Hypothesis pro-
poses that big colonies might get bigger and small clusters might
even not reach the colony status.
At this point, one should know that colony size (the num-
ber of cells in a colony) will matter, but only under optimized
conditions. To avoid discrepancies and ensure reproducibility, the
ideal condition would be to run the CFE assay under chemi-
cally defined and controlled culture medium conditions, using
recombinant growth factors instead of serum, but this can be
cost prohibitive. Moreover, what combination of factors is nec-
essary to expand mesenchymal progenitors in vitro remains to be
defined. We propose, however, that colony number, colony size,
and progenitors phenotype be tested every time serum change is
necessary.
DOES COLONY SIZE RELATE TO STEMNESS?
Colony forming ability is not exclusive to the mesenchymal sys-
tem (Queensberry et al., 1974; Dexter, 1979; Nicola and Metcalf,
1986). A similar in vitro assay has been widely used to quan-
tify hematopoietic progenitor cells. In the past, this was the only
quantification tool, but it was replaced by the development of
more meticulous flow cytometric phenotyping methods, which is
now mostly utilized to quantify and identify hematopoietic stem
cells and progenitors, although the colony assay remains widely
used. It must be clear, however, that cell transplantation into
myeloablated animals is the only way to fully identify bona fide
long-term hematopoietic stem cells (Morrison et al., 1995; Gazit
et al., 2008).
Hematopoietic stem cells and progenitor colony forming abil-
ity is observed when cells are cultured in semi-solid culture
medium, which maintains them in close proximity to each other,
as they proliferate in the presence of specific growth factors
(Queensberry et al., 1974; Dexter, 1979; Nicola and Metcalf,
1986). Unlike the CFU-f assay, which is used to quantify MSCs
and committed progenitors indiscriminately, the colony form-
ing assay can be used to quantify lymphoid, erythroid, myeloid,
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and multipotent progenitors separately depending on the com-
bination of specific growth factors added to the culture system
(Stanley et al., 1971; Dexter, 1979; Urabe et al., 1979; Nicola
and Metcalf, 1986; Quesenberry et al., 1987). Hematopoietic
progenitors grow at different culture rates and present distinct
morphologies in vitro, allowing identification and quantification
of different progenitors separately and quickly.
One major observation from the hematopoietic colony-
forming assay is that committed progenitors start to proliferate
early (day 1 of culture), and develop into distinct colonies in 5–10
days. On the other hand, most primitive progenitors can take a
few days to exit the quiescent stage and will eventually form full
colonies after 9–14 days in culture (Stanley et al., 1971; Dexter,
1979; Urabe et al., 1979; Nicola and Metcalf, 1986; Quesenberry
et al., 1987). Although primitive progenitors take longer to form
colonies, the colonies generated are typically 2–4 times larger than
those derived from committed progenitors. This in vitro behavior
is in full accordance with in vivo observations, as hematopoi-
etic stem cells are typically quiescent however, when properly
stimulated, achieve higher proliferative rates compared to other
progenitors (Carow et al., 1993; Ponchio et al., 1995; Hao et al.,
1996; Petzer et al., 1996; Oh and Humphries, 2012). For these
reasons it is often inferred that the larger the colony, the more
primitive the progenitor it had been derived from.
A similar line of observation could be applied to the colony-
forming unit fibroblast assay. In a 13-day culture, the committed
progenitors will initiate proliferation faster in vitro giving rise to
colonies, but these cells will rapidly undergo clonal exhaustion.
Conversely, uncommitted progenitors will take longer to activate
the proliferation cascade, and do not arrest during the culture
period and thus result in larger colonies. Indeed, it is not unusual
to correlate colony size with primitiveness of the cell of origin.
A question remains unanswered: “Is thirteen days sufficient for
all multipotential stem cells to enter the cell cycle and become
highly proliferative cells ex vivo?” Primitive stem cells are likely
to remain deeply quiescent or proliferate very slowly in vivo.
When placed in vitro, they may require longer to leave the qui-
escent stage but, once stimulated, their proliferative rate is likely
to increase beyond that observed for intermediate progenitors.
Many hypothesize that the most quiescent mesenchymal stem
cells might take longer to start proliferation in vitro, which means
that a few small/medium colonies may not be representative
of exhausted committed progenitors, but rather indicate yet-to-
proliferate stem cells (Figure 3). This possibility challenges many
assumptions derived from the CFU-f assay, and suggests that
colony size may not necessarily reflect primitiveness. Cells in
colonies derived from committed progenitors are usually large
stellate-like cells, while in colonies derived from stem cells are
often small and fusiform (Gothard et al., 2013). In this case,
cell morphology may be a useful tool to tell apart exhausted or
expanding small- and medium-sized colonies.
As discussed above, growth factor concentrations in FBS dif-
fers among serum lots, and does have significant outcomes on
CFU-f size, frequency and even colony morphology. Viewed in
terms of the Selective Growth Hypothesis (Figure 2), distinct
categories of mesenchymal progenitors may be dependent upon
different growth factors (and concentrations) to proliferate (or
remain quiescent) in vitro.
FIGURE 3 | It is generally accepted that most primitive progenitors,
upon exiting the lag growth phase, will reach higher proliferation rates
than committed progenitors. However, recent data indicate that a few
progenitors might require a longer time to enter replicative cycles in vitro.
We and others hypothesize that, if cultured longer, these progenitors might
originate larger colonies.
PROGENITORS ADHESION IN VITRO
Previously published data imply that all human bone marrow-
derived mesenchymal stem cells and progenitors with the abil-
ity to form fibroblast-like cell colonies adhere within 2–48 h
in vitro, followed by a fetal bovine serum-dependent growth
(Friedenstein, 1976; Castro-Malaspina et al., 1980; Kastrinaki
et al., 2008; Kuznetsov et al., 2009). After this period of incu-
bation, non-adherent cells are discarded and adherent cells are
further expanded for at least 10 additional days. The original
protocol designed by Friedenstein and coworkers, and corrobo-
rated by several other laboratories (Friedenstein et al., 1966, 1970;
Owen and Friedenstein, 1988), established the requirement for a
72-h adhesion period prior to the elimination of non-adherent
cells. This adhesion period is still considered a critical step for iso-
lation and expansion of these progenitors. It has been described
that bone marrow stromal cells must adhere to a substrate in vitro
for their survival and proliferation, regardless their differentia-
tion potential (Bruder et al., 1997; Pittenger et al., 1999; Dominici
et al., 2006). Notwithstanding, authors demonstrate that stromal
progenitor cells, or at least a subset of them, can be maintained in
stirred suspension cultures for 21 days, andmight even proliferate
when induced by a combination of cytokines and growth factors
(Baksh et al., 2003). Which specific stromal progenitors subsets
remain in suspension are yet to be determined.
The average colony forming efficiency for normal human adult
bone marrow may vary from 1 to 30 per 1 × 105 nucleated mar-
row cells (Beresford et al., 1994; Oreffo et al., 1998; Doucet et al.,
2005; Bernardo et al., 2007; Kuznetsov et al., 2009). As previ-
ously discussed (Kuznetsov et al., 2009), such different values
might be the result of either distinct cell isolation/preparation
procedures or cell culture conditions, the latter meaning FBS
capacity to induce progenitors proliferation in vitro. Although
proliferation status has been a very useful tool to evaluate FBS
quality, progenitors adhesion capacity, not usually considered, is
crucial for colony forming efficiency and does affect the results.
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It is not clear, however, if and how different concentrations of
growth factors and cytokines in FBS would impact progeni-
tors adhesion in vitro. Most recently, Di Maggio and coworkers
(Di Maggio et al., 2012) demonstrated that highly proliferative
multipotent progenitors can be isolated from the non-adherent
fraction, after 3 days, when bone marrow cells are cultured in the
presence of FGF2. In addition to previous observations (Baksh
et al., 2003), these data indicate that mesenchymal progenitors,
or at least a subset, might change its adhesion properties accord-
ingly as growth factors and cytokines concentration change in
FBS. Currently, it is difficult to precise how much time mes-
enchymal stem cells and progenitors need to adhere in vitro,
and how it is influenced by FBS growth factors concentrations.
Further studies will be necessary as progenitors adhesion repre-
sents one crucial step when it comes to mesenchymal progenitors
isolation.
PERSPECTIVE
The fibroblast-like colony-forming assay is simple to perform:
cells are plated; progenitors adhere to the substrate and pro-
liferate in a short culture period; cells are fixed and stained;
colonies with more than 50 cells are counted. The number of
progenitors in a given cell population can be easily approxi-
mated. Colony-forming efficiency results, however, depend upon
an optimized procedure and several steps must be optimized to
provide linear and reproducible data. Herein, our purpose was to
revisit this classic method and open a discussion based on three
issues to assist assay performance and data interpretation, but
mostly to help researchers establish in their labs a standardized
procedure. It is critical to optimize the ability of the cells to pro-
liferate in response to growth factors present in the FBS, or any
other source used, and this is commonly neglected due to the
“quantification-only” use of the method. As a renewable source
for tissue regeneration, in vitro cell expansion is almost always
required for MSC populations, meaning that these cells will not
be used as primary cultures, but only after, at least, 3 passages. It
would be expected that after several rounds of expansion, most
primitive progenitors and stem cells would take over the culture
at the expense of other progenitors. Nevertheless, this has not
been well elucidated so far and it is not known howmesenchymal
population responds to different growth factors concentration
in different serum lots. Although several research groups have
described different strategies MSCs, the cell populations obtained
and expanded remain heterogeneous in terms of stem cells and
committed progenitors regardless of the method used for iso-
lation (Muraglia et al., 2000; Sacchetti et al., 2007). No current
method ensures isolation of a pure population of MSCs, or even
whether this is desirable but this fact, the lack of standards,
makes difficult understanding of the biology and true potential of
these cells.
For these reasons it would be interesting that researchers estab-
lish a “surveillance system” when working with mesenchymal
progenitors isolation and expansion. We therefore propose a list
of three procedures recommended as controls. First, it would be
highly desirable for each laboratory to keep a standard collec-
tion of bone marrow samples to be used as references for testing
serum lots. Conceptually, each lab could select representative
bone marrow samples, split each of them into equal aliquots (10,
20, 30, or as many as possible), freeze all at the same time, and
cryopreserve (Figure 4). These aliquots will be used to test serum
“quality” every time changes of lots are necessary.
As a second control instrument, the influence of FBS in pro-
genitors adhesion should be evaluated, regarding colony forming
efficiency (Figure 5). In one group (we suggest triplicate), bone
marrow cells are incubated in culturemedium supplemented with
control serum. After 72 h, non-adherent cells are discarded and
adherent cells are cultured for 10 additional days also in culture
medium supplemented with control FBS. In another group, bone
marrow cells are incubated in culture medium supplemented
with testing serum. After 72 h, non-adherent cells are discarded
and adherent cells are culture for 10 additional days in culture
medium supplemented with control FBS. The main objective of
the assay is to analyze if different serum lots contribute to colony
forming efficiency change at the expense of cell adhesion or cell
proliferation.
Mesenchymal progenitors’ self-renewal capacity can be tested
by evaluating the ability of expanded clones to originate sec-
ondary colonies upon replating. As a third parameter, we propose
the secondary colony forming efficiency assay (Figure 6). One
thousand cells from the primary colony-forming cultures may be
replated and cultured for additional 10 days. Cells are, then, fixed
and stained. It is important to highlight that, in all three assays
colony numbers, and colony size must be rigorously evaluated
and compared.
FIGURE 4 | In order to establish a “surveillance system” when working
with mesenchymal progenitors isolation and expansion, it is
suggested that each laboratory keep a standard collection of bone
marrow samples to be used as references for testing serum lots.
Conceptually, each lab could select representative bone marrow samples,
split each of them into equal aliquots (10, 20, 30, or as many as possible),
freeze all at the same time, and cryopreserve. These aliquots will then be
thawed and used to test serum “quality” every time changes of lots are
necessary. From time to time, bone marrow collection must be renewed.
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FIGURE 5 | FBS influence on progenitor cell adhesion in vitro must
be tested. In group (A), bone marrow cells are incubated in culture
medium supplemented with control serum. After 72 h, non-adherent
cells are discarded and adherent cells are cultured for 10 additional
days also in culture medium supplemented with control FBS. In group
(B), bone marrow cells are incubated in culture medium supplemented
with testing serum. After 72 h, non-adherent cells are discarded and
adherent cells are culture for 10 additional days in culture medium
supplemented with control FBS. Colony numbers and size must be
evaluated.
FIGURE 6 | Secondary colonies assay. Bone marrow cells are incubated
in culture medium supplemented with control or testing FBS. Seventy-two
hours later, non-adherent cells are discarded and adherent cells are cultured
in culture medium supplemented with control or testing serum for 10
additional days. Later, cells are tripsinized and single-cell suspension
prepared. One thousand cells are subsequently replated and incubated for
10 additional days in culture medium supplemented with testing or control
serum. Numbers and size of secondary colonies must be evaluated.
It is clear that cell behavior in vivo and in vitro changes
from person to person, from animal to animal, even among syn-
geneic siblings, and over time in the same individual. We propose
that these three strategies combining in-colony proliferation rate
analyses with colonies formation and quantification, progenitors
adhesion, and recloning ability, if used as a lab surveillance instru-
ment, will assist in the development of a greater understanding of
the biology of MSCs and other adherent populations in vitro. We
would like to propose the creation of control guidelines which
will facilitate the identification and isolation of long-term stem
cells and short-term progenitors as a crucial step to better explore
their potential and define their applicability in the cell therapy
and bioengineering fields.
ACKNOWLEDGMENTS
We must thank Professor Radovan Borojevic and Professor
Adriana Cesar Bonomo for their enthusiastic and provoca-
tive discussions, and support which inspired this perspective.
This work was directly supported by Ministry of Science and
Technology (MCT) through the Brazilian National Council
for Scientific and Technological Development – CNPq, and
Carlos Chagas Filho Foundation for Research Support in Rio de
Janeiro – FAPERJ; by grants from the DOD (W81XWH-11-1-
0684) PC100829 CA093900 and the National Institute of Health
(AR0568903, R44 DE022493-02A10, DE022493, DK082481).
This work is also supported, in part, by the Intramural Program
of the National Institute on Aging, NIH. PC100829 CA093900
1U54CA163124-01.
REFERENCES
Andreeva, E. R., Pugach, I. M., Gordon, D., and Orekhov, A. N. (1998). Continuous
subendothelial network formed by pericyte-like cells in human vascular bed.
Tissue Cell 30, 127–135. doi: 10.1016/S0040-8166(98)80014-1
Baksh, D., Davies, J. E., and Zandstra, P. W. (2003). Adult human bone marrow-
derived mesenchymal progenitor cells are capable of adhesion-independent
survival and expansion. Exp. Hematol. 31, 723–732. doi: 10.1016/S0301-
472X(03)00106-1
Barry, F., Boynton, R., Murphy, M., Haynesworth, S., and Zaia, J. (2001). The
SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human
mesenchymal stem cells. Biochem. Biophys. Res. Commun. 289, 519–724. doi:
10.1006/bbrc.2001.6013
Barry, F. P., Boynton, R. E., Haynesworth, S., Murphy, J. M., and Zaia, J. (1999).
The monoclonal antibody SH-2, raised against human mesenchymal stem cells,
recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun.
265, 134–139. doi: 10.1006/bbrc.1999.1620
Beresford, J. N., Joyner, C. J., Devlin, C., and Triffitt, J. T. (1994). The effects of
dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation
of human marrow stromal cells in vitro. Arch. Oral Biol. 39, 941–947. doi:
10.1016/0003-9969(94)90077-9
Bernardo, M. E., Avanzini, M. A., Perotti, C., Cometa, A. M., Moretta, A., Lenta,
E., et al. (2007). Optimization of in vitro expansion of human multipotent
mesenchymal stromal cells for cell-therapy approaches: further insights in the
search for a fetal calf serum substitute. J. Cell. Physiol. 211, 121–130. doi:
10.1002/jcp.20911
Bianco, P. (2011). Minireview: the stem cell next door: skeletal and hematopoi-
etic stem cell “niches” in bone. Endocrinology 152, 2957–2962. doi: 10.1210/en.
2011-0217
Bianco, P., Cao, X., Frenette, P. S., Mao, J. J., Robey, P. G., Simmons, P. J.,
et al. (2013). The meaning, the sense and the significance: translating the
science of mesenchymal stem cells into medicine. Nat. Med. 19, 35–42. doi:
10.1038/nm.3028
Bianco, P., Costantini, M., Dearden, L. C., and Bonucci, E. (1988). Alkaline phos-
phatase positive precursors of adipocytes in the human bone marrow. Br. J.
Haematol. 68, 401–403. doi: 10.1111/j.1365-2141.1988.tb04225.x
Bruder, S. P., Jaiswal, N., and Haynesworth, S. E. (1997). Growth kinetics, self-
renewal, and the osteogenic potential of purified human mesenchymal stem
cells during extensive subcultivation and following cryopreservation. J. Cell.
Frontiers in Cell and Developmental Biology | Stem Cell Research March 2014 | Volume 2 | Article 7 | 6
Cordeiro-Spinetti et al. MSC optimized in vitro manipulation
Biochem. 64, 278–294. doi: 10.1002/(SICI)1097-4644(199702)64:2<278::AID-
JCB11>3.0.CO;2-F
Caplan, A. I. (1991). Mesenchymal stem cells. J. Orthop. Res. 9, 641–650. doi:
10.1002/jor.1100090504
Caplan, A. I. (2007). Adult mesenchymal stem cells for tissue engineering versus
regenerative medicine. J. Cell. Physiol. 213, 341–347. doi: 10.1002/jcp.21200
Carow, C. E., Hangoc, G., and Broxmeyer, H. E. (1993). Human multipotential
progenitor cells (CFU-GEMM) have extensive replating capacity for secondary
CFU-GEMM: an effect enhanced by cord blood plasma. Blood 81, 942–949.
Castro-Malaspina, H., Gay, R. E., Resnick, G., Kapoor, N., Meyers, P., Chiarieri,
D., et al. (1980). Characterization of human bone marrow fibroblast colony-
forming cells (CFU-F) and their progeny. Blood 56, 289–301.
Corselli, M., Chen, C.-W., Sun, B., Yap, S., Rubin, J. P., and Péault, B. (2011). The
tunica adventitia of human arteries and veins as a source of mesenchymal stem
cells. Stem Cells Dev. 21, 1299–1308. doi: 10.1089/scd.2011.0200
Crisan, M., Chen, C.-W., Corselli, M., Andriolo, G., Lazzari, L., and Péault, B.
(2009). Perivascular multipotent progenitor cells in human organs. Ann. N. Y.
Acad. Sci. 1176, 118–123. doi: 10.1111/j.1749-6632.2009.04967.x
Crisan, M., Huard, J., Zheng, B., Sun, B., Yap, S., Logar, A., et al. (2008a).
Purification and culture of human blood vessel-associated progenitor cells.
Curr. Protoc. Stem Cell Biol. 86, 295–309. doi: 10.1002/9780470151808.
sc02b02s4
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., et al. (2008b).
A perivascular origin for mesenchymal stem cells in multiple human organs.
Cell Stem Cell 3, 301–313. doi: 10.1016/j.stem.2008.07.003
Da Silva Meirelles, L., Chagastelles, P. C., and Nardi, N. B. (2006). Mesenchymal
stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119,
2204–2213. doi: 10.1242/jcs.02932
Dennis, J. E., Carbillet, J.-P., Caplan, A. I., and Charbord, P. (2002). The STRO-1+
marrow cell population is multipotential. Cells Tissues Organs 170, 73–82. doi:
10.1159/000046182
Dexter, T. M. (1979). Cell interactions in vitro. Clin. Haematol. 8, 453–468.
Di Maggio, N., Mehrkens, A., Papadimitropoulos, A., Schaeren, S., Heberer, M.,
Banfi, A., et al. (2012). FGF-2 Maintains a niche-dependent population of
self-renewing highly potent non-adherent mesenchymal progenitors through
FGFR2c. Stem Cells 30, 1455–1464. doi: 10.1002/stem.1106
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause,
D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stro-
mal cells. the international society for cellular therapy position statement.
Cytotherapy 8, 315–317. doi: 10.1080/14653240600855905
Doucet, C., Ernou, I., Zhang, Y., Llense, J.-R., Begot, L., Holy, X., et al. (2005).
Platelet lysates promotemesenchymal stem cell expansion: a safety substitute for
animal serum in cell-based therapy applications. J. Cell. Physiol. 205, 228–236.
doi: 10.1002/jcp.20391
Friedenstein, A. J. (1976). Precursor cells of mechanocytes. Int. Rev. Cytol. 47,
327–359. doi: 10.1016/S0074-7696(08)60092-3
Friedenstein, A. J., Chailakhjan, R. K., and Lalykina, K. S. (1970). The development
of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and
spleen cells. Cell Tissue Kinet. 3, 393–403.
Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., and
Keiliss-Borok, I. V. (1974a). Stromal cells responsible for transferring the
microenvironment of the hemopoietic tissues. Cloning in vitro and retransplan-
tation in vivo. Transplantation 17, 331–340. doi: 10.1097/00007890-197404000-
00001
Friedenstein, A. J., Deriglasova, U. F., Kulagina, N. N., Panasuk, A. F., Rudakowa,
S. F., Luriá, E. A., et al. (1974b). Precursors for fibroblasts in different popula-
tions of hematopoietic cells as detected by the in vitro colony assay method. Exp.
Hematol. 2, 83–92.
Friedenstein, A. J., Latzinik, N. W., Grosheva, A. G., and Gorskaya, U. F. (1982).
Marrow microenvironment transfer by heterotopic transplantation of freshly
isolated and cultured cells in porous sponges. Exp. Hematol. 10, 217–227.
Friedenstein, A. J., Piatetzky-Shapiro, I. I., and Petrakova, K. V. (1966).
Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16,
381–390.
Gazit, R., Weissman, I. L., and Rossi, D. J. (2008). Hematopoietic stem cells
and the aging hematopoietic system. Semin. Hematol. 45, 218–224. doi:
10.1053/j.seminhematol.2008.07.010
Gothard, D., Dawson, J. I., and Oreffo, R. O. C. (2013). Assessing the potential
of colony morphology for dissecting the CFU-F population from human bone
marrow stromal cells. Cell Tissue Res. 352, 237–247. doi: 10.1007/s00441-013-
1564-3
Hao, Q. L., Thiemann, F. T., Petersen, D., Smogorzewska, E. M., and Crooks, G.
M. (1996). Extended long-term culture reveals a highly quiescent and primitive
human hematopoietic progenitor population. Blood 88, 3306–3313.
Horwitz, E. M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I.,
Marini, F. C., et al. (2005). Clarification of the nomenclature forMSC: The inter-
national society for cellular therapy position statement. Cytotherapy 7, 393–395.
doi: 10.1080/14653240500319234
Jones, E. A., Kinsey, S. E., English, A., Jones, R. A., Straszynski, L., Meredith,
D. M., et al. (2002). Isolation and characterization of bone marrow multi-
potential mesenchymal progenitor cells. Arthritis Rheum. 46, 3349–3360. doi:
10.1002/art.10696
Kastrinaki, M.-C., Andreakou, I., Charbord, P., and Papadaki, H. A. (2008).
Isolation of human bone marrow mesenchymal stem cells using different
membrane markers: comparison of colony/cloning efficiency, differentiation
potential, and molecular profile. Tissue Eng. Part C. Methods 14, 333–339. doi:
10.1089/ten.tec.2008.0173
Kuznetsov, S. A., Mankani, M. H., Bianco, P., and Robey, P. G. (2009). Enumeration
of the colony-forming units-fibroblast from mouse and human bone mar-
row in normal and pathological conditions. Stem Cell Res. 2, 83–94. doi:
10.1016/j.scr.2008.07.007
Latsinik, N. V., and Epikhina, S. Y. (1974). Adhesive properties of hematopoietic
and lymphoid cells forming fibroblast colonies in monolayer cultures. Bull. Exp.
Biol. Med. 76, 1459–1461. doi: 10.1007/BF00787562
Maier, C. L., Shepherd, B. R., Yi, T., and Pober, J. S. (2010). Explant outgrowth,
propagation and characterization of human pericytes. Microcirculation 17,
367–380. doi: 10.1111/j.1549-8719.2010.00038.x
Mannello, F., and Tonti, G. A. (2007). Concise review: no breakthroughs for human
mesenchymal and embryonic stem cell culture: conditioned medium, feeder
layer, or feeder-free; medium with fetal calf serum, human serum, or enriched
plasma; serum-free, serum replacement nonconditioned medium, o. Stem Cells
25, 1603–1609. doi: 10.1634/stemcells.2007-0127
Morrison, S. J., Uchida, N., and Weissman, I. L. (1995). The biology of
hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 11, 35–71. doi:
10.1146/annurev.cb.11.110195.000343
Muraglia, A., Cancedda, R., and Quarto, R. (2000). Clonal mesenchymal progeni-
tors from human bone marrow differentiate in vitro according to a hierarchical
model. J. Cell Sci. 113(Pt 7), 1161–1166.
Nicola, N. A., and Metcalf, D. (1986). Specificity of action of colony-stimulating
factors in the differentiation of granulocytes and macrophages. Ciba Found.
Symp. 118, 7–28.
Oh, I.-H., and Humphries, R. K. (2012). Concise review: multidimensional
regulation of the hematopoietic stem cell state. Stem Cells 30, 82–88. doi:
10.1002/stem.776
Oreffo, R. O., Bord, S., and Triffitt, J. T. (1998). Skeletal progenitor cells and ageing
human populations. Clin. Sci. (Lond). 94, 549–555.
Owen, M., and Friedenstein, A. J. (1988). Stromal stem cells: marrow-derived
osteogenic precursors. Ciba Found. Symp. 136, 42–60.
Péault, B. (2012). Are mural cells guardians of stemness?: from pluri-
to multipotency via vascular pericytes. Circulation 125, 12–13. doi:
10.1161/CIRCULATIONAHA.111.073445
Petzer, A. L., Hogge, D. E., Landsdorp, P. M., Reid, D. S., and Eaves, C.
J. (1996). Self-renewal of primitive human hematopoietic cells (long-term-
culture-initiating cells) in vitro and their expansion in defined medium. Proc.
Natl. Acad. Sci. U.S.A. 93, 1470–1474. doi: 10.1073/pnas.93.4.1470
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D.,
et al. (1999). Multilineage potential of adult human mesenchymal stem cells.
Science 284, 143–147. doi: 10.1126/science.284.5411.143
Ponchio, L., Conneally, E., and Eaves, C. (1995). Quantitation of the quiescent frac-
tion of long-term culture-initiating cells in normal human blood and marrow
and the kinetics of their growth factor-stimulated entry into S-phase in vitro.
Blood 86, 3314–3321.
Queensberry, P. J., Bealmear, P., Ryan, M., and Stohlman, F. (1974). Serum colony
stimulating and inhibiting factors in irradiated germfree and conventional mice.
Br. J. Haematol. 28, 531–539. doi: 10.1111/j.1365-2141.1974.tb06672.x
Quesenberry, P. J., McNiece, I. K., Robinson, B. E., Woodward, T. A., Baber, G. B.,
McGrath, H. E., et al. (1987). Stromal cell regulation of lymphoid and myeloid
differentiation. Blood Cells 13, 137–146.
www.frontiersin.org March 2014 | Volume 2 | Article 7 | 7
Cordeiro-Spinetti et al. MSC optimized in vitro manipulation
Russell, K. C., Phinney, D. G., Lacey, M. R., Barrilleaux, B. L., Meyertholen, K.
E., and O’Connor, K. C. (2010). In vitro high-capacity assay to quantify the
clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals
a complex hierarchy of lineage commitment. Stem Cells 28, 788–798. doi:
10.1002/stem.312
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio,
I., et al. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids
can organize a hematopoietic microenvironment. Cell 131, 324–336. doi:
10.1016/j.cell.2007.08.025
Sarugaser, R., Hanoun, L., Keating, A., Stanford, W. L., and Davies, J. E. (2009).
Human mesenchymal stem cells self-renew and differentiate according to a
deterministic hierarchy. PLoS ONE 4:e6498. doi: 10.1371/journal.pone.0006498
Satomura, K., Krebsbach, P., Bianco, P., and Gehron Robey, P. (2000).
Osteogenic imprinting upstream of marrow stromal cell differentiation. J. Cell.
Biochem. 78, 391–403. doi: 10.1002/1097-4644(20000901)78:3%3C391::AID-
JCB5%3E3.0.CO;2-E
Shi, S., and Gronthos, S. (2003). Perivascular niche of postnatal mesenchymal stem
cells in human bone marrow and dental pulp. J. Bone Miner. Res. 18, 696–704.
doi: 10.1359/jbmr.2003.18.4.696
Shih, I. M. (1999). The role of CD146 (Mel-CAM) in biology and pathol-
ogy. J. Pathol. 189, 4–11. doi: 10.1002/(SICI)1096-9896(199909)189:1<4::AID-
PATH332>3.0.CO;2-P
Stanley, E. R., Bradley, T. R., and Sumner, M. A. (1971). Properties of the
mouse embryo conditioned medium factor(s) stimulationg colony formation
by mouse bone marrow cells grown in vitro. J. Cell. Physiol. 78, 301–317. doi:
10.1002/jcp.1040780219
Taichman, R. S.,Wang, Z., Shiozawa, Y., Jung, Y., Song, J., Balduino, A., et al. (2010).
Prospective identification and skeletal localization of cells capable of multilin-
eage differentiation in vivo. Stem Cells Dev. 19, 1557–1570. doi: 10.1089/scd.
2009.0445
Tuli, R., Tuli, S., Nandi, S., Wang, M. L., Alexander, P. G., Haleem-Smith,
H., et al. (2003). Characterization of multipotential mesenchymal progenitor
cells derived from human trabecular bone. Stem Cells 21, 681–693. doi:
10.1634/stemcells.21-6-681
Urabe, A., Murphy, M. J., Haghbin, M., and Gee, T. S. (1979). Erythroid progen-
itors (BFU-e and CFU-e) in acute leukaemia. J. Clin. Pathol. 32, 666–669. doi:
10.1136/jcp.32.7.666
Wagner, J., Kean, T., Young, R., Dennis, J. E., and Caplan, A. I. (2009). Optimizing
mesenchymal stem cell-based therapeutics. Curr. Opin. Biotechnol. 20, 531–536.
doi: 10.1016/j.copbio.2009.08.009
Zannettino, A. C. W., Harrison, K., Joyner, C. J., Triffitt, J. T., and Simmons,
P. J. (2003). Molecular cloning of the cell surface antigen identified by the
osteoprogenitor-specific monoclonal antibody, HOP-26. J. Cell. Biochem. 89,
56–66. doi: 10.1002/jcb.10481
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 30 October 2013; paper pending published: 28 November 2013; accepted: 24
February 2014; published online: 27 March 2014.
Citation: Cordeiro-Spinetti E, de Mello W, Trindade LS, Taub DD, Taichman RS
and Balduino A. (2014) Human bone marrow mesenchymal progenitors: perspectives
2014.00007
This article was submitted to Stem Cell Research, a section of the journal Frontiers in
Cell and Developmental Biology.
Copyright © 2014 Cordeiro-Spinetti, de Mello, Trindade, Taub, Taichman and
Balduino. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Cell and Developmental Biology | Stem Cell Research March 2014 | Volume 2 | Article 7 | 8
on an optimized in vitro manipulation. Front. Cell Dev. Biol. 2:7. doi: 10.3389/fcell.
